Name: Sayla H.Hometown: Portland, ORStatus: In treatmentAdvocacy Goal: Oral Parity, Access to Care Sayla was diagnosed earlier last year and is currently in treatment. She’s determined to use her experience to help other women, and is empowered to advocate for women fighting ovarian cancer through OCRA’s Advocate Leader program. Tell us about your ovarian cancer … Continued
Name: Elise D.Hometown: Durham, NHStatus: 13-Year SurvivorAdvocacy Goal: Access to Care Elise feels lucky that she was diagnosed with early-stage ovarian cancer, and being an Advocate Leader allows her to fight for women who may not be able to fight for themselves. Tell us about your ovarian cancer journey. In the summer of 2005, I … Continued
Over 250 ovarian cancer survivors will travel from across the country to attend OCRFA’s Ovarian Cancer National Conference in Washington DC on July 13-15 Reserve your spot today and join our welcoming community of survivors, caregivers and experts for an inspirational weekend packed with empowering information and new friendships. Registration includes: Sign up now to … Continued
(June 11, 2018) OCRFA, who has hosted Super Saturday in the Hamptons for the past 20 years is moving our iconic event to Manhattan. Super September will be held Thursday evening, September 27, and Friday, September 28. According to the New York Post, Page Six, “It’s the end of an era for Super Saturday. The … Continued
(June 6, 2018) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, and to organizational transparency and accountability, as we continue to strive toward a cure for … Continued
Don’t miss your chance to hear top experts speak at the “Ask the Experts” session at OCRFA’s Ovarian Cancer National Conference. Ask the Experts panelists include: We’ve extended our Ask the Experts Q&A session, giving you more time to learn and more time to answer your questions about ovarian cancer research, science and clinical trials. … Continued
(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from ovarian cancer researchers such as Dr. Anil Sood of MD Anderson and Dr. Dineo Khabele of … Continued
Donate Now It was August of 2001 when I awoke one evening with a stabbing pain in my side that was so serious, I headed straight to the emergency room. I left with a diagnosis of “depression” and a bottle of painkillers. Something inside me – a gut feeling I can’t explain – told me … Continued
(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed by hormone replacement therapy (HRT). Eight hundred and seventy two women were followed for around 7.5 years … Continued
(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued
(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much of the tumor … Continued
(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued
Get email updates about research news, action alerts, and ways to join the fight.
